• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Australian Journal of Pharmacy >Sigma downplays Amcal Max to embrace new strategy
【24h】

Sigma downplays Amcal Max to embrace new strategy

机译：Sigma淡化了Amcal Max以采用新策略

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

SIGMA Pharmaceuticals has drawn back from its Amcal Max strategy according to a recent report in the Australian Financial Review.Instead, the company would focus efforts on its 'Embrace' strategy, which has been considered a success for the company's pharmacy division.Embrace is product-for-price strategy that binds pharmacies to a three-year contract to buy from Sigma's wholesale division, including over-the-counter products and generic drugs covering many popular prescription medicines.
机译：根据《澳大利亚金融评论》（Australian Financial Review）的最新报告，SIGMA Pharmaceuticals退出了Amcal Max战略，取而代之的是，该公司将专注于其``Embrace''战略，该战略已被视为该公司药房的成功之举。定价策略，将药房与三年期合同绑定，从Sigma的批发部门购买，包括非处方药和涵盖许多流行处方药的仿制药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号